5 terminated, 4 not yet recruiting, 3 active not recruiting, 3 completed. 12 Phase 1, 4 Phase 2, 2 Phase 3.
Follow BioRay Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy Zuberitamab 1000mg, Cyclosporine - Primary Membranous Nephropathy | Phase 3 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 150 | 2026-10-01 | 2026-09-21 |
| A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors BR113 for injection - Advanced Solid Tumors | Phase 1 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 258 | 2026-08-01 | 2026-08-07 |
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia BR2251, Febuxostat - Gout and Hyperuricemia | Phase 2 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 160 | 2026-04-01 | 2026-03-27 |
| Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies BRY812 for injection - Advanced Gynecological Malignancies | Phase 2 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 56 | 2025-12-01 | 2025-12-31 |
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL Orelabrutinib, Zuberitamab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 65 | 2025-10-01 | 2026-04-02 |
| A Study of BR111 in Patients With Advanced Malignancies BR111 for Injection - Advanced Malignancies | Phase 1 | Recruiting | BioRay Pharmaceutical Co., Ltd. | 166 | 2025-04-24 | 2025-11-21 |
| A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy Zuberitamab 600mg, Zuberitamab 1000mg, cyclosporine - Primary Membranous Nephropathy | Phase 2 | Active not recruiting | BioRay Pharmaceutical Co., Ltd. | 135 | 2024-11-13 | 2025-11-20 |
| A Study of BRY805 in Participants With Advanced Solid Tumors BRY805 injection - Advanced Solid Tumor | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 13 | 2024-03-13 | 2025-11-21 |
| Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects BR201, Cosentyx（Secukinumab ） - Psoriasis | Phase 1 | Completed | BioRay Pharmaceutical Co., Ltd. | 88 | 2024-02-21 | 2025-06-24 |
| A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies BR115 for injection - Advanced Solid Malignancies | Phase 1 | Suspended | BioRay Pharmaceutical Co., Ltd. | 120 | 2024-02-19 | 2025-11-21 |
| A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies BRY812 for injection - Advanced Malignancies | Phase 1 | Recruiting | BioRay Pharmaceutical Co., Ltd. | 164 | 2023-10-10 | 2025-12-30 |
| Phase I/II Clinical Study of 1A46 Drug Substance 1A46 Drug Substance - Advanced Malignancies | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 4 | 2023-09-12 | 2025-02-19 |
| A Phase I Study of BR108 in Hematological Malignancies BR108 injection - Hematologic Malignancy | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 8 | 2023-03-18 | 2025-11-21 |
| Clinical Study of BR105 Injection BR105 injection - Advanced Malignancies | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 31 | 2022-04-19 | 2026-03-17 |
| Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection HS627(210mg/7ml), HS627(420mg/14ml), Perjeta - Similarity of Pharmacokinetics and Safety | Phase 1 | Completed | BioRay Pharmaceutical Co., Ltd. | 180 | 2022-04-11 | 2023-07-11 |
| A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors BR101 - Advanced Solid Tumor | Phase 1 | Completed | BioRay Pharmaceutical Co., Ltd. | 15 | 2021-08-11 | 2025-11-21 |
| Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection HS632, Omalizumab (Xolair®) - Similarity of Pharmacokinetics and Safety | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 1 | 2020-10-15 | 2025-11-21 |
| Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel HS627, Pertuzumab - Breast Cancer | Phase 3 | Active not recruiting | BioRay Pharmaceutical Co., Ltd. | 408 | 2020-06-28 | 2025-11-21 |
Breast Neoplasms (1) · Gout (1) · Hematologic Neoplasms (1) · Hyperuricemia (1) · Lymphoma, B-Cell, Marginal Zone (1) · Psoriasis (1)
Injections (5) · Cyclosporine (2) · pertuzumab (2) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Docetaxel (1) · Febuxostat (1) · Omalizumab (1) · Trastuzumab (1) · Vincristine (1) · orelabrutinib (1) · secukinumab (1)
China (15)
Haibo Wang, M.D (1) · Jing Zhang, Dr. Pharm (1) · Xiaojie Wu, Dr. Pharm (1) · Xinxin Cao, doctor (1) · Yu Cao, Doctor (1) · Zefei Jiang, M.D (1)